Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance
Open Access
- 18 October 2004
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 127 (3), 308-310
- https://doi.org/10.1111/j.1365-2141.2004.05169.x
Abstract
We hypothesized that the presence of monoclonal free light chains (FLC) in the serum of patients with monoclonal gammopathy of undetermined significance (MGUS) is a marker of clonal evolution and a risk factor for progression. Forty-seven patients with MGUS and documented progression to myeloma or related malignancy were compared with 50 age- and gender-matched patients with MGUS and no evidence of progression after 5 or more years of follow-up. The presence of an abnormal kappa/lambda FLC ratio in the serum was associated with a higher risk of MGUS progression (relative risk 2·5; 95% confidence interval: 1·6–4·0; P < 0·001).Keywords
This publication has 10 references indexed in Scilit:
- Long-term follow-up of IgM monoclonal gammopathy of undetermined significanceBlood, 2003
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBritish Journal of Haematology, 2003
- Serum test for assessment of patients with Bence Jones myelomaThe Lancet, 2003
- Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light ChainsClinical Chemistry, 2002
- Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain MyelomaClinical Chemistry, 2002
- Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaJournal of Clinical Oncology, 2002
- Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaJournal of Clinical Oncology, 2002
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002
- Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myelomaBlood, 2001
- “Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-UpMayo Clinic Proceedings, 1993